所有图片(1)

文件

Y0000626

氨丁三醇

Name: 氨丁三醇
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

登录查看公司和协议定价

所有图片(1)

别名:

酮咯酸三羟甲基氨基甲烷盐, 托拉多尔, （±）-5-苄基-2,3-二氢-1H-吡咯嗪-1羧酸三羟甲基氨基甲烷盐

经验公式（希尔记法）:

C₁₅H₁₃NO₃ · C₄H₁₁NO₃

CAS号:

74103-07-4

分子量:

376.40

MDL编号:

MFCD00887595

PubChem化学物质编号:

329831061

NACRES:

NA.24

等级

pharmaceutical primary standard

API family

ketorolac

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

格式

neat

储存温度

2-8°C

SMILES string

NC(CO)(CO)CO.OC(=O)C1CCn2c1ccc2C(=O)c3ccccc3

InChI

1S/C15H13NO3.C4H11NO3/c17-14(10-4-2-1-3-5-10)13-7-6-12-11(15(18)19)8-9-16(12)13;5-4(1-6,2-7)3-8/h1-7,11H,8-9H2,(H,18,19);6-8H,1-3,5H2

InChI key

BWHLPLXXIDYSNW-UHFFFAOYSA-N

Gene Information

human ... PTGS1(5742) , PTGS2(5743)

正在寻找类似产品? Visit 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Ketorolac trometamol for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

1356326

1356315

1356337

1356348

PHR2493

PHR2494

象形图

GHS06

警示用语：

Danger

危险声明

H301 - H315 - H319 - H335

预防措施声明

P261 - P264 - P270 - P301 + P310 - P302 + P352 - P305 + P351 + P338

危险分类

Acute Tox. 3 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

靶器官

Respiratory system

储存分类代码

6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

分析证书(COA)

输入产品批号来搜索分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

为方便起见，与您过往购买产品相关的文件已保存在文档库中。

访问文档库

难以找到您所需的产品或批次号码？

如何查找产品货号

在网站页面上，产品编号会附带包装尺寸/数量一起显示（例如：T1503-25G）。请确保在“产品编号”字段中仅输入产品编号 (示例: T1503).

示例

T1503

货号

25G

包装规格/数量

其它示例：

705578-5MG-PW

PL860-CGA/SHF-1EA

MMYOMAG-74K-13

1000309185

输入内容 1.000309185)

遇到问题？欢迎随时联系我们技术服务寻求帮助

如何查找COA批号

批号可以在产品标签上"批“ （Lot或Batch）字后面找到。

Aldrich 产品

如果您查询到的批号为 TO09019TO 等，请输入去除前两位字母的批号：09019TO。
如果您查询到的批号含有填充代码（例如05427ES-021），请输入去除填充代码-021的批号：05427ES。
如果您查询到的批号含有填充代码（例如 STBB0728K9），请输入去除填充代码K9的批号：STBB0728。

未找到您寻找的产品？

部分情况下，可能未在线提供COA。如果搜索不到COA，可在线索取。

索取COA

Pharmacokinetic comparison of ketorolac after intracameral, intravitreal, and suprachoroidal administration in rabbits.

Meizi Wang et al.

Retina (Philadelphia, Pa.), 32(10), 2158-2164 (2012-10-27)

To investigate the concentrations and pharmacokinetics of ketorolac in the rabbits by three different routes of administrations: a single intracameral, intravitreal, and suprachoroidal injection. Fifty-four New Zealand white rabbits received ketorolac (250 μg/0.05 mL) in one eye by a single

An update on the use of ophthalmic ketorolac tromethamine 0.4%.

Henry D Perry et al.

Expert opinion on pharmacotherapy, 7(1), 99-107 (2005-12-24)

Ketorolac tromethamine 0.4% ophthalmic solution, a recent reformulation of the original ketorolac tromethamine 0.5% solution, is indicated for the reduction of ocular pain and burning/stinging following cataract and refractive surgery. Studies have demonstrated that ketorolac tromethamine 0.4% has equivalent efficacy

The pharmacokinetics of ketorolac after single postoperative intranasal administration in adolescent patients.

David R Drover et al.

Anesthesia and analgesia, 114(6), 1270-1276 (2012-04-03)

Ketorolac tromethamine (ketorolac) administration reduces postoperative opioid requirements. The pharmacokinetic characteristics of intranasal ketorolac tromethamine in children have not been characterized. Our objective of this study was to determine the pharmacokinetics of a single intranasal dose of ketorolac in adolescent

A review of intranasal ketorolac tromethamine for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level.

Andy He et al.

Current medical research and opinion, 28(12), 1873-1880 (2012-10-27)

An intranasal (IN) formulation of ketorolac was recently FDA approved in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level. The aim of this paper is to provide an overview

Persistent hyperalgesia in the cisplatin-treated mouse as defined by threshold measures, the conditioned place preference paradigm, and changes in dorsal root ganglia activated transcription factor 3: the effects of gabapentin, ketorolac, and etanercept.

Hue Jung Park et al.

Anesthesia and analgesia, 116(1), 224-231 (2012-12-12)

Painful neuropathy is a dose-limiting side effect in cancer chemotherapy. To characterize this phenomenon, we examined pain behavior and analgesic actions in a mouse model of cisplatin polyneuropathy. Male C57BL/6 mice received intraperitoneal cisplatin or saline (2.3 mg/kg/d) every other

查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门

文件